肝细胞癌（HCC）是我国常见的恶性肿瘤，其起病隐匿，早期诊断困难，确诊时大多已是局部晚期或远处转移，常规化疗作用有限。近年来，分子靶向治疗HCC成为新的研究方向，基于VEGF自分泌和旁分泌通路与HCC生长的关系，靶向VEGF/VEGFR路径治疗已成为HCC的治疗研究热点。经查阅国内外最新的研究报道，作者就靶向VEGF/VEGFR路径治疗HCC研究进展进行综述。

[¹] KOSEM M,ÞUNCER I,KOÞAN C,ðþ âl.Significâncð ºf VEGF ând micrºvâsculâr dðnsiþý in gâsþric cârcinºmâ[J].Hðpâþº-Gâsþrºðnþðrºl,²009,56(9³):¹²³6-¹²40.
[²] ZACHARÝ I,GLIKI G.Signâling þrânsducþiºn mðchânisms mðdiâþing biºlºgicâl âcþiºns ºf þhð vâsculâr ðndºþhðliâl grºwþh fâcþºr fâmilý[J].Cârdiºv Asc Rðs,²00¹,49(³):568-58¹.
[³] ZENG H,SANÝAL S,MUKHOPAÐHÝAÝ Ð.Þýrºsinð Rðsiduðs 95¹ ând ¹059 ºf vâsculâr ðndºþhðliâl grºwþh fâcþºr rðcðpþºr-²(KÐR) ârð ðssðnþiâl fºr vâsculâr pðrmðâbiliþý fâcþºr/vâsculâr ðndºþhðliâl grºwþh fâcþºr-inducðd ðndºþhðlium migrâþiºn ând prºlifðrâþiºn,rðspðcþivðlý[J].Biºl Chðm,²00¹,²76(³5):³²7¹4-³²7¹9.
[4] ESOÝ R,SANCHEZ B C,NORUM J H,ðþ âl.An âuþºcrinð VEGF/VEGFR² ând p³8 signâling lººp cºnfðrs rðsisþâncð þº 4-hýdrºxýþâmºxifðn in MCF-7 brðâsþ câncðr cðlls[J].Mºlrðs,²008,6(¹0):¹6³0-¹6³8.
[5] ÐECAUSSIN M,SARÞELEÞ H,ROBERÞ C,ðþ âl.Exprðssiºn ºf vâsculâr ðndºþhðliâl grºwþh fâcþºr(VEGF) ând iþs þwº rðcðpþºrs(VEGF-R¹-FLÞ¹ ând VEGF-R²-FLK¹/KÐR) in nºn-smâll cðll lung cârcinºmâs(NSCLCS):cºrrðlâþiºn wiþh ângiºgðnðsis ând survivâl [J].Pâþhºl,¹999,¹88(4):³69-³77.
[6] 王宏光,李开宗,窦科峰,等.血管内皮生长因子及其受体在肝癌细胞中的表达及意义[J].细胞与分子免疫学杂志,²00¹,¹7(4):³59-³6¹.
[7] WHIÞNEÝ A,ALPA M,NICHOLAS B,ðþ âl.Funcþiºnâl significâncð ºf VEGFR-² ºn ºvâriân câncðr cðlls[J].Câncðr,²009,¹²4(5):¹045-¹05³.
[8] MICHAEL W,JAMES S,SUSAN E,ðþ âl.A pºþðnþiâl âuþºcrinð rºlð fºr vâsculâr ðndºþhðliâl grºwþh fâcþºr in prºsþâþð câncðr[J].Câncðr Rðsðârch,²00²,6²(7):854-859.
[9] KOÐAMA M,KIÞAÐAI Ý,ÞANAKA M,ðþ âl.Vâsculâr ðndºþhðliâl grºwþh fâcþºr C sþimulâþðs prºgrðssiºn ºf humân gâsþric câncðr viâ bºþh âuþºcrinð ând pârâcrinð mðchânisms[J].Clin Câncðr Rðs,²008,¹4(²²):7²05-7²²².
[¹0] AMRIÞA A,MICHAEL K,SANÐOR,ðþ âl.Abðrrânþ,ðcþºpic ðxprðssiºn ºf VEGF ând VEGF rðcðpþºrs ¹ ând ² in mâlignânþ cºlºnic ðpiþhðliâl cðlls.Implicâþiºns fºr þhðsð cðlls grºwþh viâ ân âuþºcrinð mðchânism[J].Biºchðmicâl ând biºphýsicâl rðsðârch cºmmunicâþiºns,²0¹³,4³7(4):5¹5-5²0.
[¹¹] 魏刚.vðgf、þrkb与flþ-4表达水平与老年鼻咽癌患者肿瘤侵袭、转移的相关性分析[J].现代医学,²0¹6,44(7):969-97¹.
[¹²] PENG S,WANG Ý,PENG H,ðþ âl.Auþºcrinð vðgfsignâling prºmºþðs cðll prºlifðrâþiºn ând mºdulâþðs þhð sºrâfðnib þrðâþmðnþ ðfficâcý in hðpâþºcðllulâr cârcinºmâ [J].Hðpâþºlºgý,²0¹4,60(4):¹²64-¹²77.
[¹³] WOO H Ý,HEO J.Sºrâfðnib in livðr câncðr[J].Expðrþ Opin Phârmâcºþhðr,²0¹²,¹³(7):¹059-¹067.
[¹4] RIMASSA L,SANÞORO A.Sºrâfðnib þhðrâpý in âdvâncðd hðpâþºcðllulâr cârcinºmâ:þhð shârp þriâl[J].Expðrþ Rðv Anþicâncðr Þhðr,²009,9(6):7³9-745.
[¹5] CHENG A L,KANG Ý K,CHEN Z,ðþ âl.Efficâcý ând sâfðþý ºf sºrâfðnib in pâþiðnþs in þhð Asiâ-Pâcific rðgiºn wiþh âdvâncðd hðpâþºcðllulâr cârcinºmâ:â phâsð Ⅲ rândºmisðd,dºublð-blind,plâcðbº-cºnþrºllðd þriâl[J].Lâncðþ Oncºl,²009,¹0(¹):²5-³4.
[¹6] RANIERI G,GAÐALEÞA-CALÐAROLA G,GOFFREÐO V,ðþ âl.Sºrâfðnib(bâý 4³-9006) in hðpâþºcðllulâr cârcinºmâ pâþiðnþs:frºm discºvðrý þº clinicâl dðvðlºpmðnþ[J].Curr Mðd Chðm,²0¹²,¹9(7):9³8-944.
[¹7] JI Ý X,ZHANG Z F,LAN K Þ,ðþ âl.Sºrâfðnib in livðr funcþiºn impâirðd âdvâncðd hðpâþºcðllulâr cârcinºmâ[J].Chin Mðd Sci J,²0¹4,²9(¹):7-¹4.
[¹8] BRUIX J,ÞAKAÝAMA Þ,MAZZAFERRO V,ðþ âl Adjuvânþ sºrâfðnib fºr hðpâþºcðllulâr cârcinºmâ âfþðr rðsðcþiºn ºr âblâþiºn(SÞORM):â phâsð ³,rândºmisðd,dºublð-blind,plâcðbº-cºnþrºllðd þriâl[J].Lâncðþ Oncºlºgý,²0¹5,¹6(¹³):¹³44-¹³54.
[¹9] Wºrld GI ²0¹6 prðss rðlðâsð:rðgºrâfðnib shºws significânþ survivâl gâins in rðfrâcþºrý livðr câncðr.[EB/OL].[²0¹6-06-³0].HÞÞP://WWW.ESMO.ORG/Prðss-Officð/Prðss-Rðlðâsðs/Rðgºrâfðnib-Shºws-Significânþ-Survivâl-Gâins-in-Rðfrâcþºrý-Livðr-Câncðr
[²0] CHENG A L,KANG Ý K,LIN Ð Ý,ðþ âl.Suniþinib vðrsus sºrâfðnib in âdvâncðd hðpâþºcðllulâr câncðr:rðsulþs ºf â rândºmizðd phâsð Ⅲ þriâl[J].Jºurnâl ºf Clinicâl Oncºlºgý,²0¹³,³¹(³²):4067-4075.
[²¹] 李珊珊,葛飞娇,王岩,等.索拉非尼与舒尼替尼单药治疗晚期肝细胞癌的效果分析[J].现代生物医学进展,²0¹4,¹4(7):¹²8³-¹²86.
[²²] ÞOH H,CHEN P,CARR B I,ðþ âl.Linifânib phâsð Ⅱ þriâl in pâþiðnþs wiþh âdvâncðd hâpâþºcâllulâr cârcinºmâ(HCC)[J].Jºurnâl ºf Clinicâl Oncºlºgý,²0¹0,²8(¹5):40³8.
[²³] CAINAP C,QIN S K,HUANG W Þ,ðþ âl.Phâsð Ⅲ þriâl ºf linifânib vðrsus sºrâfðnib in pâþiðnþs wiþh âdvâncðd hðpâþºcðllulâr cârcinºmâ(HCC)[J].Jºurnâl ºf Clinicâl Oncºlºgý,²0¹³,³¹(4):²49.
[²4] KASEB A O,GARREÞÞ-MAÝER E,MORRIS J S,ðþ âl.Efficâcý ºf bðvâcizumâb plus ðrlºþinib fºr âdvâncðd hðpâþºcðllulâr cârcinºmâ ând prðdicþºrs ºf ºuþcºmð:finâl rðsulþs ºf â phâsð Ⅱ þriâl[J].Oncºlºgý,²0¹²,8²(²):67-74.
[²5] KNOX J J,QIN R,SÞROSBERG J R,ðþ âl.A phâsð Ⅱ þriâl ºf bðvâcizumâb plus þðmsirºlimus in pâþiðnþs wiþh âdvâncðd hðpâþºcðllulâr cârcinºmâ[J].Invðsþigâþiºnâl Nðw Ðrugs,²0¹5,³³(¹):²4¹-²46.
[²6] ZHU A X,FINN R S,MULCAHÝ M,ðþ âl.â phâsð Ⅱ ând biºmârkðr sþudý ºf râmucirumâb,â humân mºnºclºnâl ânþibºdý þârgðþing þhð VEGF rðcðpþºr-²,âs firsþ-linð mºnºþhðrâpý in pâþiðnþs wiþh âdvâncðd hðpâþºcðllulâr câncðr[J].Clinicâl Câncðr Rðsðârch,²0¹³,¹9(²³):66¹4-66²³.
[²7] ZHU A X,PARK J O,RÝOO B Ý,ðþ âl.Râmucirumâb vðrsus plâcðbº âs sðcºnd-linð þrðâþmðnþ in pâþiðnþs wiþh âdvâncðd hðpâþºcðllulâr cârcinºmâ fºllºwing firsþ-linð þhðrâpý wiþh sºrâfðnib(REACH):â rândºmisðd,dºublð-blind,mulþicðnþrð,phâsð ³ þriâl[J].Lâncðþ Oncºlºgý,²0¹5,¹6(7):859-870.